Asia Pacific Metabolomics Services Market Outlook and Strategic Insights by 2028

The metabolomics services market in APAC is expected to grow from US$ 110.42 million in 2021 to US$ 438.91 million by 2028; it is estimated to grow at a CAGR of 21.8% from 2021 to 2028.

The several economies across the region are creating significant opportunities for the key market players to expand their businesses. The majority of players concentrate on big countries, owing to the large population suffering from chronic diseases in these countries. With rising production costs against their practices, the healthcare companies are striving to produce sufficient revenue to entertain their investors. The markets in a few growing economies are expected to be an essential part of offering more reliable and profitable growth opportunities for the major players to expand their industry. Advancements in biotechnology have increased the demand for diagnostics in the healthcare market, encouraging the introduction of more analytical systems and facilitating the shift toward personalized medicine. There are new opportunities in infectious disease testing, molecular oncology, and pharmacogenomics in emerging countries. Hence, healthcare companies can target patients or consumers in several nations. Various players in the industry have been investing a significant amount of their revenue in R&D activities to develop better and advanced products and technologies to be used in the healthcare industry.  Thus, the rising number of diseases such as cancer and advancements in several countries are likely to boost the market and are anticipated to provide significant growth opportunities to the players operating in the market during the forecast period.

As a result of the ongoing COVID-19 pandemic, the healthcare sector is under tremendous pressure. The containment and social distancing measures have led to disruption in supply chains. Moreover, the demand for efficient diagnostics and treatments of COVID-19 has gained huge paramount importance in Asia Pacific. India, China, Japan, and South Korea are among the countries in the region that are experiencing various adverse effects due to the pandemic, which include damaged socioeconomics, inflation, low GDPs, and unemployment surge. Countries such as China, Japan, Singapore, and South Korea engaged in rapid clinical trials. High costs of operations in western countries drive the flow of medical affairs outsourcing to Asia Pacific. To leverage these opportunities, pharmaceutical companies in this region gaining expertise on new and changing regulatory environments for drugs, devices, and in-vitro diagnostics. New or improved regulations are implemented frequently in Asia, including changes in GMP standards, drug price controls, and medical device regulatory systems. Third-party guidance and advice are required for any new standard acquisition or improvements. Increasingly, third-party outsourcing service providers are playing a more significant role in supporting the associated markets in Asia Pacific. As of 2021, the market has stabilized owing to control procedures, awareness among people, vaccine development and administration, and supportive government policies boosting business growth.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the metabolomics services market. The APAC metabolomics services market is expected to grow at a good CAGR during the forecast period.

 

APAC Metabolomics Services Market Revenue and Forecast to 2028 (US$ Million)

APAC Metabolomics Services Market Segmentation

APAC Metabolomics Services Market – By Service Type

• Targeted Metabolomics Service
• Untargeted Metabolomics Service

APAC Metabolomics Services Market – By Application

• Pharmaceutical and Biotechnology Industry
  • Biomarker Discovery
  • Drug Discovery
  • Toxicological Testing
  • Others
• Agritech
• Environment

APAC Metabolomics Services Market- By Country

• Japan
• China
• India
• Australia
• South Korea
• Rest of APAC

APAC Metabolomics Services Market-Companies Mentioned

• BASF SE
• BGI
• biocrates life sciences ag
• C-CAMP
• Chenomx Inc.
• Creative Proteomics
• Fred Hutchinson Cancer Research Center
• RTI International

Asia Pacific Metabolomics Services Report Scope